"Breakthrough Cancer Treatment Unveiled in Northwestern Medicine Study"

A recent study conducted by Northwestern faculty has identified metixene, a central nervous system small-molecule inhibitor drug, as a promising therapeutic agent for the treatment of metastatic breast cancer and brain metastases. The drug killed cancer cells in mice models, decreased the size of breast tumors, and increased the lifespan of mice with brain metastases. Metixene has minimal reported side effects in humans, making it a strong candidate for further investigation and potential use in human clinical trials.